HTB South

TB coinfection

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Breakthrough for treating XDR-TB and ameliorating TB-IRIS

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Universal treatment of multi-drug resistant TB is possible within current budgets with generic production

Shortened nine-month MDR-TB treatment works well in children and adolescents

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection

Xpert TB test has important advantages but does not reduce morbidity

Moxifloxacin and rifapentine: we need better trials

EMA recommends conditional approval of bedaquiline for drug resistant TB with orphan drug status

Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”

RIFAQUIN study demonstrates once-weekly dosing during follow-up phase of TB treatment

Study indicates rifampicin dose should be higher

Counter-intuitive result of IPT plus ART trial

Combining Xpert and LAM urine testing improves TB diagnostic sensitivity

Tuberculosis MVA85A vaccine trial shows lack of efficacy in infants

RIFAQUIN trial proves new TB regimen

Paediatric TB: glimpses of PK data and a potential new approach to drug development

New UNITAID grants focus on paediatric HIV, TB and malaria

FDA approves bedaquiline for MDR TB: first new tuberculosis drug in half a century

The case for pre-approval access to bedaquiline

US fund additional $11 million for Xpert TB diagnostics in 14 countries

Costs for rapid TB test reduced by 40%

Pharmacokinetics of old and new TB Drugs

Important advances in TB drug development

Update on bedaquline phase II trial

Need for expanded access to two promising MDR TB drugs

ZAMSTAR study suggests active case finding in households reduces TB prevalence

A court case and a model show how poor conditions are fueling a TB epidemic in prisons

Randomised trial of ART in TB patients with high CD4 counts

WHO Guidelines on guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

IPT for adults: Should the Mantoux test have been removed from WHO guidelines?

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART

When to start ART in patients co-infected with TB: results from two trials presented at CROI

41st Union World Conference on Lung Health, 11-15 November 2010, Berlin

Faster conversion rates with TMC-207 versus placebo plus OBT for the treatment of MDR-TB

Xpert MTB-RIF validation study from Tanzania

Gene Xpert demonstrates good sensitivity and specificity but at high cost

Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children

Cambodian trial shows early ART reduces mortality in patients with very TB with very low CD4 counts

Intensified TB case finding is feasible

Botswana IPT trial: Continuous isoniazid superior to 6 months short course

40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease 3-7 December 2009, Cancun, Mexico

Cepheid Gene Xpert diagnostic technology for TB

Adherence of TB patients on self-administered treatment

High mortality and poor record keeping for TB in-patients in Kwazulu-Natal Hospital

Factors affecting survival of XDR TB patients

TB screening algorithm to determine who can safely go onto IPT and who needs to be treated

Analysis of the emergence of drug resistant TB in a South African mine

Systematic review of rifamycin studies shows eight months might be beneficial

WHO TB guidelines

Overview of TB-related studies at IAS

TMC207 open label trial for MDR-TB

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in HIV-infected and HIV/TB coinfected children in South Africa

Nevirapine: fluconazole and TB treatment

HIV and TB from CROI

TMC207 reduces time to sputum conversion in phase II trial in patients with drug-resistant TB

Relationship between TB IRIS and drug-resistant TB

High risk of stavudine substitution associated with TB treatment

WHO global TB control report highlights that 25% of TB-related deaths occur in HIV-positive people

Treatment outcomes in patients who received rifampicin with nevirapine or efavirenz